Sarepta Therapeutics, Inc.SRPT
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · sarepta.com
Biotechnology company developing and commercializing RNA-targeted and gene therapies for rare diseases, notably Duchenne muscular dystrophy.
Key ratios
FCF / Sales
4.1%TTM
2025
-14.0%2024
-18.0%2023
-46.4%
Net margin
-6.9%TTM
2025
-32.5%2024
12.4%2023
-43.1%
ROA
-1.1%TTM
2025
-11.2%2024
3.8%2023
-5.2%
ROE
-9.5%TTM
2025
-53.5%2024
19.7%2023
-86.2%
Revenue growth
15.6%2025
2024
53.0%2023
33.3%
Track SRPT in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer